Prognostic factors in patients with hepatocellular carcinoma treated with Sorafenib
M Pinter, W Sieghart, F Hucke, I Graziadei, W Vogel, A Maieron, R Königsberg, A Weissmann, G Kornek, J Matejka, R Stauber, R Buder, B Grünberger, M Schöniger-Hekele, C Müller, M Peck-Radosavljevic · Zeitschrift für Gastroenterologie · 2011 · Heft 05
Bibliografische Angaben
Zusammenfassung
Purpose: We aimed to identify prognostic factors for patients with hepatocellular carcinoma (HCC) treated with sorafenib and to evaluate the efficacy of sorafenib with respect to liver function. Patients and methods: In this retrospective study, 148 HCC patients received sorafenib 400mg bid in 11 Austrian institutions. Seventy-eight HCC patients treated with best supportive care (BSC) in the pre-sorafenib era served as control. Results: Child-Pugh (CP) stage A/B for HCC patients within Barcelona Clinic Liver Cancer (BCLC) stage B and C was n=76/55 for sorafenib and n=17/22 for BSC. Seventeen (sorafenib) and 39 (…
